Send us Fan Mail

This week, I’m taking a curious, watch-and-see approach to GLP-1 medications—things like semaglutide, Ozempic, Wegovy. We’ll cover the research-backed potential benefits, the side effects, what happens after stopping, and why the conversation is about much more than just weight.

No judgment, no pressure, just information, reflection, and a reminder that your choices are personal and worth considering thoughtfully.

Tune in if you want to explore GLP-1 medications from a place of curiosity and clarity.

Quote of the Week:

“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Will Durant

Citations

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002.

2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. Diabetes, Obesity and Metabolism.

3. SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity. New England Journal of Medicine.

4. Drucker, D. J. (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.

5. Baggio, L. L., & Drucker, D. J. (2007). Biology of Incretins. Gastroenterology.

Let’s go, let’s get it done.

Get more information at: http://projectweightloss.org